CVS Health has made a change at the top, with David Joyner taking over as CEO from Karen Lynch. This move comes as the company grapples with waning profits and a sliding stock price, which has dropped by nearly 20% this year alone. Shares fell by another 13% on the day of the announcement. Higher medical costs in the insurance unit, Aetna, and reduced spending at CVS retail pharmacies have been significant hurdles for the company.

In August, CVS reduced its full-year profit expectations and announced plans to cut $2 billion in costs over the next few years. The company expects third-quarter earnings per share to range between $1. 05 and $1. 10, with higher medical costs than initially projected. Investors were warned not to rely on the previous profit guidance.

CVS will report its third-quarter earnings on November 6. The move to replace Lynch comes after major shareholder Glenview Capital pushed for changes, and the board considered splitting the insurance and retail businesses. Joyner, who oversaw the pharmacy services business, is expected to address industry challenges and implement operational improvements. Lynch has stepped down from the board, while Joyner will join it and Farah will become executive chairman.

CVS Shakes Up Top Leadership in Face of Challenges

Actions